The goal of this observational study is to find out if the researchers can predict the number of nurses needed on hospital wards (units) from patient hospital data. The main question it aims to answer is:
Is it possible to predict nurse staffing requirements from routinely recorded data in hospital systems?
Researchers will ask nurses about their views of nurse staffing tools and what support they need for staffing decisions. They will analyse data from hospital IT systems.

开始日期2025-05-01

申办/合作机构

The University of Southampton

[+4]

ISRCTN13053675

/ Recruiting临床4期

Establishing a UK platform to collect tumour samples and perform DNA/RNA sequencing for the development of personalised cancer vaccines

开始日期2024-08-31

申办/合作机构

NHS England

NCT06560931

/ Active, not recruitingN/AIIT

Defining, Recognising and Escalating Maternal Early Deterioration (DREaMED): Decreasing Inequality Through Improved Outcomes.

Every year more than 700,000 women give birth in the United Kingdom. Of these at least 8700 nearly die - called a "near-miss", and 70 die. Many more women suffer harm, often with effects lasting for life. Women from less wealthy areas and particular ethnic groups are more likely to come to harm.
"Vital signs" include measurements of blood pressure, heart and breathing rates. Doctors and midwives use tools that score vital signs to spot women becoming unwell. These tools are called "Modified Obstetric Early Warning Scores" (MOEWS). Despite their use, poor outcomes still occur. This may be because MOEWS use only the most recent vital signs. Using extra data like blood tests may help spot unwell people earlier.
The study aims to reduce poor outcomes for women giving birth. The study will find better ways of describing, spotting, and treating women becoming unwell.
The study have planned four linked projects to develop an electronic advanced maternal obstetric early warning system (eMOEWS). Patient and Public (PPIE) collaborators have developed this work with CI's. The study work closely with them throughout this project.
Once the study has completed these four projects, they plan to carry out a trial to assess whether the new eMOEWS leads to better outcomes than the existing tools.

开始日期2023-05-02

申办/合作机构

University of Oxford

[+3]

100 项与 NHS England 相关的临床结果

登录后查看更多信息

0 项与 NHS England 相关的专利（医药）

登录后查看更多信息

127

项与 NHS England 相关的文献（医药）

2025-07-04·Education for Primary Care

Becoming a designated prescribing practitioner: a pilot educational course

Article

作者: Micallef, Ricarda ; Nathwani, Puja ; May, Leanne

With the need for an increase in non-medical prescribers (NMPs) in the NHS, there is a lack of designated prescribing practitioners (DPPs) in place to supervise trainee NMPs. An educational five-session course was developed using the Royal Pharmaceutical Society's (RPS) competency framework to support allied healthcare professional groups (HCPs) in fulfilling the role. The aim of this study was to evaluate the knowledge and confidence of learners after their attendance, on the competencies required to become a DPP. Pre and post training questionnaires were used after sessions, identifying pre-existing knowledge and confidence in the competency framework, alongside changes after the sessions, using Likert 1-10 scales, along with job details and previous DPP experience. This study was ethically approved. Responses (n = 80) represented all HCPs including pharmacists, nurses and paramedics. The average knowledge levels increased 4.08 after the session, from 5.09 for all HCPs to 9.17 (p< 0.0001). The average confidence levels increased 3.71 from 5.49 to 9.20 for all HCP's (p< 0.0001). Over half (64%, n = 52) stated they were very likely to become DPPs following this course. Almost all (90%, n = 72) stated that they did not require any other additional training. Additional roll outs of this educational course could help increase the number of NMPs in the NHS, aligning well with the aims and objectives of the NHS Long-term and access recovery plan. A notable increase was felt by the HCPs in their knowledge and confidence from the sessions, therefore this study shows the benefit of running such a programme.

2025-05-01·CLINICAL MEDICINE

Transforming transnasal endoscopy services: A multicentre service evaluation pilot project

Article

作者: Despott, Edward ; Asilmaz, Esra ; Hussein, Mohamed ; Sehgal, Vinay ; Stevens, Sophie ; Banerjee, Saswata ; Dunn, Jason ; Grimes, Michael ; Marelli, Laura ; Hoque, Sami ; Eldragini, Mohsen ; Padaruth, Shamima ; Saramosing, Juriese ; Raymond, Regina ; Knights, Eleanor ; Albusoda, Ahmed ; Rajendran, Arun ; Kumar, Mayur ; Coda, Sergio ; Sultana-Miah, Farhana ; Maxwell, Paul ; Gulati, Shraddha

OBJECTIVES:

To assess the impact of pilot transnasal endoscopy (TNE) services on workforce efficiency, allocated procedure times and patient tolerance of procedures. The aim was to also understand the challenges of setting up a TNE service.

METHODS:

Six-month data were collected from ten sites. Data captured included productivity, performance, workforce numbers, facilities and quality metrics. A patient survey was done to capture patients' experience. An eight Likert-style and open question survey was designed and used. Pilot sites were visited using a semi-structured interview process.

RESULTS:

About 30% of the pilot sites carried out the TNE service outside of the endoscopy unit. There is an overall 25% improvement in workforce efficiency with TNE. Of those patients who had both a TNE and an oesophagogastroduodenoscopy, 78% reported that having the TNE procedure was a better experience. All sites reported that they will continue providing TNE beyond the pilot period. Sites carrying out TNE reported a high satisfaction with the services. Overall satisfaction with the quality of TNE imaging was very high.

CONCLUSIONS:

This multicentre pilot project shows evidence that the integration of TNE services has a positive impact in increasing capacity and patient satisfaction. This should set the scene for scaling this up on a wider capacity. TNE services, particularly with an introduction into outpatients, will improve service capacity in endoscopy, patients will tolerate the procedures more, national 2-week wait and Faster Diagnosis Standard targets will improve, and it is potentially more cost efficient overall.

2025-01-02·British journal of neurosurgery

The volume-outcome relationship for endoscopic transsphenoidal pituitary surgery for benign neoplasm: analysis of an administrative dataset for England

Article

作者: Rennie, Catherine ; Phillips, Nick ; Briggs, Tim W. R. ; Gray, William K. ; Navaratnam, Annakan V. ; Mendoza, Nigel

BACKGROUND:

Setting minimum annual volume thresholds for pituitary surgery in England is seen as one way of improving outcomes for patients and service efficiency. However, there are few recent studies from the UK on whether a volume-outcome effect exists, particularly in the era of endoscopic surgery. Such data are needed to allow evidence-based decision making. The aim of this study was to use administrative data to investigate volume-outcome effects for endoscopic transsphenoidal pituitary surgery in England.

METHODS:

Data from the Hospital Episodes Statistics database for adult endoscopic transsphenoidal pituitary surgery for benign neoplasm conducted in England from April 2013 to March 2019 (inclusive) were extracted. Annual surgeon and trust volume was defined as the number of procedures conducted in the 12 months prior to the index procedure. Volume was categorised as < 10, 10-19, 20-29, 30-39 and ≥40 procedures for surgeon volume and < 20, 20-39, 40-59, 60-79 and ≥80 procedures for trust volume. The primary outcome was repeat ETSPS during the index procedure or during a hospital admission within one-year of discharge from the index procedure.

RESULTS:

Data were available for 4590 endoscopic transsphenoidal pituitary procedures. After adjustment for covariates, higher surgeon volume was significantly associated with reduced risk of repeat surgery within one year (odds ratio (OR) 0.991 (95% confidence interval (CI) 0.982-1.000)), post-procedural haemorrhage (OR 0.977 (95% CI 0.967-0.987)) and length of stay greater than the median (0.716 (0.597-0.859)). A higher trust volume was associated with reduced risk of post-procedural haemorrhage (OR 0.992 (95% CI 0.985-0.999)), but with none of the other patient outcomes studied.

CONCLUSIONS:

A surgeon volume-outcome relationship exists for endoscopic transsphenoidal pituitary surgery in England.

项与 NHS England 相关的新闻（医药）

2024-03-05

·EndPoints

UK's NICE recommends against coverage for AstraZeneca and Daiichi's breast cancer drug Enhertu over cost-effectiveness

The UK’s National Institute for Health and Care Excellence (NICE) said Tuesday that it won’t recommend coverage of AstraZeneca and Daiichi Sankyo’s cancer drug Enhertu for treating advanced HER2-low breast cancer in adults. NICE said that while NHS England has been negotiating with the company over the price of the drug since December, they weren’t able to reach an agreement. It’s not a huge surprise — NICE’s draft guidance in September said it didn’t recommend Enhertu because of doubts around its cost-effectiveness. You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

加速审批

2024-01-08

·CPHI制药在线

2023年日本批准新药简述

关注并星标CPHI制药在线2023年，日本共批准21款新药，其中化药10款，生物药及细胞疗法11款。从药物类型来看，化药研发越来越多样化。10款化药中包括5款小分子、3款合成多肽、1款抗生素和1款小干扰RNA。本文主要从基本信息、国际注册、涉及本药的医药交易、核心专利等情况，简述2023年日本批准的化药，为行业提供一些思考。注：本文所列新药是日本医药品医疗器械综合机构（PMDA）首次批准的新活性物质；不包含化学仿制药、疫苗、血液制品、生物类似药、新适应症、新剂型、新给药途径和改变适用人群等情形。参考来源：PMDA、FDA、EMA、NMPA等各大评审局，图片自制 1.1 Cefiderocol Sulfate Tosylate 简介：Cefiderocol Sulfate Tosylate是由盐野义制药株式会社研发的一种头孢菌素类抗生素，是一种PBPs抑制剂，用于治疗细菌感染、呼吸机相关性肺炎、细菌性肺炎、医院获得性肺炎、革兰氏阴性细菌感染和泌尿系统感染。国际注册：2019-11-14美国、2020-04-23 欧盟、2023-11-30日本；中国III期。相关交易：截止目前，该药已有三起披露的合作。 2022年06月15日, 盐野义制药和Global Antibiotic Research and Development Partnership Foundation与CHAI就cefiderocol达成合作； 2022年06月16日, 盐野义制药和Nhs England就FETCROJA? (CEFIDEROCOL)达成合作； 2023年09月12日, Orchid Pharma Ltd获得Global Antibiotic Research and Development Partnership Foundation关于cefiderocol的许可。核心专利：原研化合物专利WO2010050468A1于2009-10-27申请，已进入各大主流国家。其中，中国：CN102203100B预计2029-10-27到期。美国：US9238657B2橙皮书显示2033-11-14到期，已延长。 Cefiderocol Sulfate Tosylate结构式，图片来源：说明书 1.2 Zilucoplan 简介：Zilucoplan是由Ra Pharmaceuticals Inc和比利时联合化工集团研发的一种合成多肽，是一种C5抑制剂，用于治疗重症肌无力。国际注册：2023-09-25日本、2023-10-17美国；中国暂无进展。相关交易：暂未检索到公开交易。核心专利：原研化合物/序列专利WO2015191951A3于2015-06-12申请，已进入各大主流国家。其中，中国：CN106456701B预计2035-06-12到期。美国：橙皮书显示US10106579B2于2035-06-12到期。 Zilucoplan结构式，图片来源：说明书 1.3 Tenapanor hydrochloride 简介：Tenapanor hydrochloride（盐酸替纳帕诺）是由Ardelyx Inc研发的一种First-in-Class小分子药物，是一种NHE3抑制剂，用于治疗慢性肾功能不全、高磷血症、便秘和肠易激综合征。国际注册：2019-09-12美国、2023-09-25日本；中国：原研2.4类申请上市，2023-07-12承办（复星医药和Ardelyx共同申报）。相关交易：2017年12月11日, 复星医药获得Ardelyx关于Tenapanor的许可。核心专利：原研化合物专利WO2010078449A3于2009-12-30申请，已进入各大主流国家。其中，中国：CN103819403B预计2029-12-30到期；美国：US8541448B2橙皮书显示2033-08-01到期，已延长。 Tenapanor hydrochloride结构式，图片来源：说明书 1.4 Difelikefalin 简介：Difelikefalin（地非法林）是由Ferring Pharmaceuticals及Cara Therapeutics研发的一种First-in-Class合成多肽，是一种KOR1激动剂，用于治疗瘙痒症。国际注册：2021-08-23美国、2022-04-25欧盟、2023-09-25日本；中国：III期。相关交易：截止目前，本药涉及六项交易。 2012年05月03日, Chong Kun Dang Pharmaceutical获得Cara Therapeutics关于Difelikefalin的许可； 2012年05月03日, Chong Kun Dang Pharmaceutical获得Cara Therapeutics关于Difelikefalin的许可； 2018年05月23日, 维福公司获得Cara Therapeutics关于Difelikefalin的许可； 2019年08月21日, Cara Therapeutics获得Enteris BioPharma关于Difelikefalin的许可； 2020年10月20日, Cara Therapeutics和维福就Difelikefalin达成合作； 2023年09月25日, 丸石制药获得Cara Therapeutics Inc关于KORSUVA IV Injection的许可(里程碑付款)。核心专利：原研化合物/序列专利WO2008057608A8于2007-11-12申请，已进入各大评审局。其中，中国：CN101627049B预计2027-11-13到期；美国：US7402564B1橙皮书显示2027-11-12到期。 Difelikefalin结构式，图片来源：说明书 1.5 Inclisiran sodium 简介：Inclisiran sodium（英克司兰钠）是由Alnylam Pharmaceuticals Inc研发的一种First-in-Classs iRNA，是一种PCSK9抑制剂，用于治疗高胆固醇血症、血脂障碍、颈动脉疾病、杂合子家族性高胆固醇血症和动脉粥样硬化。国际注册：2020-12-09 欧盟、2021-12-22美国、2023-08-22中国、2023-09-25 日本相关交易：本药涉及两起交易。 2013年02月04日, Alnylam Pharmaceuticals和The Medicines Company就ALN-PCS02和Inclisiran sodium达成合作； 2021年09月06日, Novartis和英国国家医疗服务体系就Inclisiran sodium达成合作。核心专利：原研化合物/序列专利WO2014089313A1于2013-12-05申请，已进入各大主流国家。其中，中国：CN104854242B预计2033-12-05到期。美国：美国橙皮书显示US10125369B2 于2034-08-18到期，已延长。 Inclisiran sodium结构式，图片来源：说明书 1.6 Lenacapavir sodium 简介：Lenacapavir sodium（来那帕韦）是由Gilead Inc研发的一种First-in-Class小分子药物，是一种Capsid抑制剂，用于治疗HIV感染。国际注册：2022-08-17欧盟、2022-12-22美国、2023-08-0日本；中国：原研5.1类申请上市，涉及两个剂型，片剂及注射液。来那帕韦片（2023-09-23承办）、来那帕韦注射液（2023-09-28承办）。相关交易：暂未检索到公开交易。核心专利：原研化合物专利WO2018035359A1于2017-08-17申请，已进入各大主流国家。其中，中国：CN109890808B，预计2037-08-17到期；美国：橙皮书显示US10071985B2于2037-08-17到期。 Lenacapavir sodium结构式，图片来源：说明书 1.7 Ritlecitinib 简介： Ritlecitinib（利特昔替尼）是由辉瑞研发的一种小分子药物，是一种JAK3抑制剂和TEC抑制剂，用于治疗斑秃。国际注册：2023-06-23美国、2023-06-26 日本、2023-09-15 欧盟、2023-10-18 中国。相关交易：暂未检索到公开交易。核心专利：原研化合物专利WO2015083028A1于2014-11-20申请，已进入各大主流国家。其中，中国：CN106061973B，预计2034-11-20到期；美国：橙皮书显示US9617258B2于2034-12-03到期，已延长。 Ritlecitinib结构式，图片来源：说明书 1.8 Futibatinib 简介：Futibatinib（福巴替尼）是由大鹏药品工业株式会社和大冢制药株式会社研发的一种小分子药物，是一种FGFR1-4拮抗剂，用于治疗胆管上皮癌和胆管癌。国际注册：2022-09-30美国、2023-06-26日本、2023-07-04欧盟。中国：暂无进展。相关交易：暂未检索到公开交易。核心专利：原研化合物专利WO2013108809A1于2013-01-17申请，已进入各大主流国家。其中，中国：CN103958512B预计2033-01-17到期；美国：橙皮书显示US10434103B2于2033-02-23到期，已延长。 Futibatinib结构式，图片来源：说明书 1.9 Pegcetacoplan 简介：Pegcetacoplan是由Apellis Pharmaceuticals Inc研发的一种合成多肽，是一种C3抑制剂，用于治疗阵发性血红蛋白尿症和地图状萎缩。国际注册：2021-05-14美国、2021-12-13欧盟、2023-03-27日本；中国：暂无进展。相关交易：2020年10月27日, Apellis和Swedish Orphan Biovitrum就Pegcetacoplan达成合作。核心专利：原研化合物/序列专利WO2014078731A3于2013-11-15申请，已进入各大主流国家。其中，中国：CN105051057B预计2033-11-15到期。美国：橙皮书显示US11292815B2，于2033-11-15到期。 Pegcetacoplan结构式，图片来源：说明书 1.10 Avatrombopag Maleate 简介：Avatrombopag Maleate（马来酸阿伐曲泊帕）是由安斯泰来制药集团研发的一种小分子药物，是一种TpoR激动剂，用于治疗血小板减少和肝脏疾病。国际注册: 2018-05-21美国、2019-06-20欧盟、2020-04-14 中国、 2023-03-27 日本。相关交易：2018年03月19日, 复星医药获得Dova Pharmaceuticals（安斯泰来合作公司）关于阿伐曲泊帕的许可。核心专利：原研化合物专利WO2003062233A1于2003-01-15申请，已进入各大主流国家。其中，中国：CN1319967C于2023-01-15已经到期。美国：橙皮书显示US7638536B2于2025-05-05到期，已延长。 Avatrombopag Maleate结构式，图片来源：说明书参考资源： 1、药物信息：各大药物说明书 2、注册信息：PMDA、FDA、EMA、NMPA等国际评审局 3、专利信息：美国橙皮书、中国专利局、欧专局等作者简介：药丸，中国药科大学硕士毕业，具有法律及药学教育背景，拥有法律资格证和专利代理师资格证，致力研究药学和专利，做一颗有价值的药丸。智药研习社1月直播预告来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com▼更多制药资讯，请关注CPHI制药在线▼点击阅读原文，进入智药研习社~

专利到期疫苗临床3期生物类似药

100 项与 NHS England 相关的药物交易

登录后查看更多信息

100 项与 NHS England 相关的转化医学

登录后查看更多信息